Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations

Current treatments that use hematopoietic progenitor cell (HPC) transplantation in acute myeloid leukemia (AML) patients substantially reduce the risk of relapse, but are limited by the availability of immune compatible healthy HPCs. Although cellular reprogramming has the potential to provide a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Salci, Kyle R, Lee, Jong-Hee, Laronde, Sarah, Dingwall, Steve, Kushwah, Rahul, Fiebig-Comyn, Aline, Leber, Brian, Foley, Ronan, Dal Cin, Arianna, Bhatia, Mickie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Regenerative Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691325/
https://www.ncbi.nlm.nih.gov/pubmed/25764124
http://dx.doi.org/10.1002/stem.1994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691325/
https://www.ncbi.nlm.nih.gov/pubmed/25764124
http://dx.doi.org/10.1002/stem.1994

Ejemplares similares